Massachusetts Financial Services Co. MA Reduces Holdings in Kymera Therapeutics, Inc. $KYMR

Massachusetts Financial Services Co. MA lowered its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 33.5% during the fourth quarter, HoldingsChannel reports. The firm owned 289,404 shares of the company’s stock after selling 145,610 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Kymera Therapeutics were worth $22,519,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC raised its stake in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Kymera Therapeutics during the second quarter worth approximately $73,000. Finally, US Bancorp DE grew its position in shares of Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after buying an additional 166 shares in the last quarter.

Insider Transactions at Kymera Therapeutics

In other news, insider Noah Goodman sold 8,264 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $87.50, for a total transaction of $723,100.00. Following the completion of the transaction, the insider owned 53,542 shares of the company’s stock, valued at approximately $4,684,925. The trade was a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at approximately $60,130,760.70. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 327,042 shares of company stock valued at $27,626,372 over the last quarter. Insiders own 16.01% of the company’s stock.

Analyst Ratings Changes

KYMR has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price target on the stock. Citigroup increased their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group lifted their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $123.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $118.90.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $89.00 on Thursday. The company has a market cap of $7.27 billion, a PE ratio of -24.18 and a beta of 2.28. The company has a fifty day moving average price of $83.69 and a two-hundred day moving average price of $74.15. Kymera Therapeutics, Inc. has a 12 month low of $24.42 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The business had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business’s revenue for the quarter was down 60.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) EPS. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.